NCT00586105已完成3 期
A Multicenter Uncontrolled Study of Sorafenib in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma
适应症
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Bayer
- 入组人数
- 39
- 主要终点
- Pharmacokinetics Measured as Area Under Curve (AUC[0-12h])
研究概览
简要总结
A multicenter uncontrolled study of sorafenib in patients with unresectable and/or metastatic renal cell carcinoma (RCC) to assess the pharmacokinetic profile, safety and tolerability, and efficacy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who have a life expectancy of at least 12 weeks
- •Patients, who suffer from unresectable and/or metastatic, measurable RCC histologically or cytologically documented. Patients with rare subtypes of RCC such as pure papillary cell tumor, mixed tumor containing predominantly sarcomatoid cells, Bellini carcinoma, medullary carcinoma, or chromophobe oncocytic tumors are excluded from study participation.
- •Patients who have received not more than one prior systemic therapy for advanced disease which was completed at least 30 days prior to the first dose of study medication.
- •Patients who have at least one uni-dimensional measurable lesion by Computed Tomography (CT)-scan or Magnetic Resonance Imaging (MRI) according to Response Evaluation Criteria in Solid Tumours (RECIST)
- •Patients with "Intermediate" or "low" risk per the Motzer score
- •Patients who have an Eastern Co-operative Oncology Group (ECOG) performance status of 0 or 1
- •Adequate bone marrow, liver and renal function at screening as assessed by the following:
- •Total bilirubin < 1.5 x the upper limit of normal.
- •Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) < 2.5 x upper limit of normal (< 5 x upper limit of normal for patients with liver involvement of their cancer).
- •Amylase and lipase < 1.5 x the upper limit of normal.
- •Serum creatinine < 2.0 x the upper limit of normal.
- •Prothrombin Time (PT) or International Normalized Ratio (INR) and Partial Thromboplastin Time (PTT) < 1.5 x upper limit of normal
排除标准
- •Previous or concurrent cancer that is distinct in primary sit or histology from the cancer being evaluated in this study EXCEPT cervical carcinoma in situ, adequately treated basal cell carcinoma, superficial bladder tumors [Ta (Noninvasive papillary carcinoma), Tis (Carcinoma in situ: "flat tumor") and T1 (Tumor invades subepithelial connective tissue)] or any cancer curatively treated > 3 years prior to study entry)
- •Patients who completed their prior systemic treatment regimen less than 30 days
- •Cardiac arrhythmias requiring anti-arrhythmic (excluding beta blockers or digoxin), symptomatic coronary artery disease or ischemia
- •Active clinically serious bacterial or fungal infections
- •Known history of human immunodeficiency virus (HIV) infection or chronic hepatitis B or C requiring current interferon treatment
- •Symptomatic metastatic brain or meningeal tumors unless the patient is > 6 months from definitive therapy, has a negative imaging studies within 4 weeks of study entry and is clinically stable with respect to the tumor at the time of study entry.
- •Patients with evidence or history of bleeding diathesis.
- •Patients with seizure disorder requiring medication
- •History of organ allograft
- •Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results
- •Pregnant or breast-feeding patients.
- •Excluded concomitant medications:
- •Concurrent anti-cancer chemotherapy, immunotherapy, or hormonal therapy except Bisphosphonates
- •Radiotherapy during study or within 3 weeks of start of study drug.
- •Biological response modifiers, such as Granulocyte-Colony Stimulating Factor (G-CFS) or Granulocyte macrophage colony-stimulating factor (GM-CFS), within 3 weeks prior to study entry or during study
- •Significant surgery within 4 weeks prior to start of study drug
- •Autologous bone marrow transplant or stem cell rescue within 4 months of study
- •Investigational drug therapy during or within 4 weeks prior to first drug administration and during the study
- •St John's Wort
- •Xiao Chai Hu Tang
- •Prior and concomitant use of Bevacizumab, and all other drugs (investigational or licensed) that target Vascular Endothelial Growth Factor (VEGF)/VEGF-Receptors, Raf-kinase inhibitors (RKI), Methyl Ethyl Ketone (MEK) or Farnesyl transferase inhibitors
研究组 & 干预措施
Sorafenib (Nexavar, BAY43-9006)
Experimental
400 mg (2 tablets of 200 mg) of sorafenib per oral (PO) twice daily (BID)
干预措施: Sorafenib (Nexavar, BAY43-9006) (Drug)
结局指标
主要结局
Pharmacokinetics Measured as Area Under Curve (AUC[0-12h])
时间窗: 12 hours after at least 21 days of uninterrupted dosing
The AUC(0-12h) was the observed AUC, calculated using a combination of linear and log trapezoidal rules, from pre-dose to 12 hours post-dose. The normalized AUC (AUC norm) is AUC (0-12h) divided by (dose \[mg\]/weight \[kg\]).
Pharmacokinetics Measured as Concentration (Cmax at Tmax and Cmin at Tmin)
时间窗: 12 hours after at least 21 days of uninterrupted dosing
Cmax (maximum concentration) was measured at the time point at which the maximum concentration (Tmax) was observed. Cmin (minimum concentration) was measured at the time point at which the minimum concentration (Tmin) was observed.
Pharmacokinetics Measured as Concentration (Cmax Normalized at Tmax and Cmin Normalized at Tmin)
时间窗: 12 hours after at least 21 days of uninterrupted dosing
Cmax (maximum concentration) was measured at the time point at which the maximum concentration (Tmax) was observed. Cmin (minimum concentration) was measured at the time point at which the minimum concentration (Tmin) was observed. The normalized variables (Cmax norm and Cmin norm) are the variables (Cmax and Cmin, see Primary Outcome Measure 2) divided by \[dose (mg)/weight (kg)\].
次要结局
- Progression Free Survival (PFS)(Number of days from date of first dose of study drug to date first observed disease progression or death (whichever was earlier) was documented up to 17.25 months)
- Overall Survival (OS)(Time from start of therapy to death up to 17.25 months)
- Time to Progression (TTP)(Time from start of study medication to clinical or radiological disease progression which ever occurs first up to 17.25 months)
- Disease Control (DC)(From start to end of study medication up to 17.25 months)
- Overall Best Response(Best response observed from start to end of study medication up to 17.25 months)
- Overall Response Duration(From PR or CR to progression or death up to 17.25 months)
- Time to Objective Response(Time from start of study medication to first documented PR or CR up to 17.25 months)
研究者
相似试验
已完成
2 期
Study Multicentre Evaluating the Effectiveness and Toxicity Sorafenib (Nexavar®) in Adult Patients With Uveal Melanoma and Metastatic DisseminationUveal MelanomaNCT02517736University Hospital, Caen32
终止
2 期
Study to Evaluate the Effects of Sorafenib if Combined With Chemotherapy (FOLFOX6 or FOLFIRI) in the Second-Line Treatment of Colorectal CancerColorectal NeoplasmsNCT00889343AIO-Studien-gGmbH101
已完成
2 期
Sorafenib in Treating Patients With Kidney Cancer That Has Spread to the BrainKidney CancerMetastatic CancerNCT00301847National Cancer Institute (NCI)44
已完成
2 期
Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent SarcomaAdult AngiosarcomaAdult Epithelioid SarcomaAdult LeiomyosarcomaAdult Malignant Fibrous HistiocytomaAdult NeurofibrosarcomaAdult Synovial SarcomaOvarian SarcomaRecurrent Adult Soft Tissue SarcomaRecurrent Uterine SarcomaStage III Adult Soft Tissue SarcomaStage III Uterine SarcomaStage IV Adult Soft Tissue SarcomaStage IV Uterine SarcomaUterine CarcinosarcomaUterine LeiomyosarcomaNCT00245102National Cancer Institute (NCI)147
已完成
2 期
Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma PatientsThyroid CarcinomaNCT02114658Bayer18